Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma

Shalev Fried*, Eden Shkury, Orit Itzhaki, Inbal Sdayoor, Ronit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Elad Jacoby, Roni Shouval, Meirav Kedmi, Ronit Marcus, Arnon Nagler, Avichai Shimoni, Abraham Avigdor

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Patients with relapsed/refractory follicular lymphoma (R/R-FL) often require multiple treatment lines. We performed a phase 1b/2 single-center clinical trial of autologous point-of-care anti-CD19 chimeric antigen receptor (CAR) T-cells in R/R-FL patients treated patients with ≥ 2 treatment lines. All 26 patients enrolled received CAR T-cell infusion at a median of 11 days after leukapheresis. Seventy-seven percent of patients had POD24. At enrollment, disease stage was III-IV in 85% of the patients, 77% had high-risk FLIPI score, and 77% had progressive disease. Grade III-IV cytokine release and immune effector cell-associated neurotoxicity syndromes occurred in 12% and 16% of the patients, respectively. Overall response rate at 1-month was 88%. The median follow-up was 15.4 months. One-year overall and progression-free survival were 100% and 63%, respectively. In conclusion, point-of-care CAR T-cell, manufactured within 11 days, induced a high response rate with an acceptable safety profile in patients with high-risk R/R-FL.

Original languageEnglish
JournalLeukemia and Lymphoma
StateAccepted/In press - 2023


  • Chimeric antigen receptor
  • follicular lymphoma
  • point-of-care


Dive into the research topics of 'Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma'. Together they form a unique fingerprint.

Cite this